Neuland Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the enhancement of capacity at its Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana.

Existing capacity - 256 KL
Existing capacity utilization - 91%
Proposed capacity addition - 120.5 KL
Period for capacity addition - within 12-18 months
Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director of the Company, categorized as Non-Executive Non-Independent, w.e.f. 12 May 2026.

Neuland Laboratories has fixed 24 July 2026 as record date for purpose of determining the shareholders eligible to receive final dividend of Rs 34 per equity share of Re 10 for FY 2026.

Net profit of Neuland Laboratories rose 664.72% to Rs 212.67 crore in the quarter ended March 2026 as against Rs 27.81 crore during the previous quarter ended March 2025. Sales rose 136.40% to Rs 776.25 crore in the quarter ended March 2026 as against Rs 328.36 crore during the previous quarter ended March 2025.

For the full year,net profit rose 39.94% to Rs 364.00 crore in the year ended March 2026 as against Rs 260.11 crore during the previous year ended March 2025. Sales rose 36.98% to Rs 2022.99 crore in the year ended March 2026 as against Rs 1476.84 crore during the previous year ended March 2025.

Powered by Capital Market - Live News